Recent Updates
Recently added Catalysts

OPRX-106

Phase 1

Human Volunteer | Small molecule | Other |Protalix BioTherapeutics, Inc. (DE)|Last Updated: Aug 4, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment18
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02107833Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy VolunteersPHASE1 COMPLETED 18Jul 1, 2014Dec 1, 2014Aug 4, 2015 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
OPRX-106DRUG -
Unlock Study Design Details